Friday, 29 March 2024


VR startup in US brings immersive drug design software to Japan

17 September 2020 | News

The software environment accelerates scientific decision making by allowing users to visualize, modify, and simulate biological and chemical compounds

Image credit- shutterstock.com

Image credit- shutterstock.com

US based virtual reality (VR) startup Nanome, Inc. has entered into an agreement with Fujitsu to bring their signature product—an immersive scientific design and collaboration platform—to the Japanese market. The software is already used by more than 15 of the top US-based biopharmaceutical companies.

Nanome became the first VR software company to launch an immersive real-time collaboration platform for scientific discovery in 2015. The software environment accelerates scientific decision making by allowing users to visualize, modify, and simulate biological and chemical compounds, facilitating effective communication of data and integrating with existing computational chemistry workflows.

Beginning this month, Fujitsu, a multinational information technology equipment and services company headquartered in Tokyo, Japan, will sell Nanome software licenses to Japanese pharmaceutical companies. This places Nanome in one of the largest markets in the world. The startup hopes to expand the partnership to address the needs of chemical engineering and materials science companies.

Since the COVID-19 pandemic began late last year, the startup's software has been used by researchers globally to evaluate the ability of antibody and small molecule drug candidates to bind the viral proteins. In June, Nanome became the first US-based company to join European Union government supercomputing efforts against SARS-CoV-2 by providing virtual reality headsets and Nanome software access to selected members of the Exscalate4Cov consortium.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account